Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.05 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 54.55% to -$0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.02 through Dec 2025, up 94.12% year-over-year, with the annual reading at -$0.02 for FY2025, 93.94% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.05 at Akebia Therapeutics, down from $0.0 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.15 in Q2 2022, with the low at -$0.51 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.14, with a median of -$0.08 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 3458.5% in 2024, then soared 133.33% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then surged by 90.0% to -$0.04 in 2022, then surged by 108.19% to $0.0 in 2023, then crashed by 3458.5% to -$0.11 in 2024, then skyrocketed by 54.55% to -$0.05 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.05, $0.0, and $0.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.